A detailed history of Geode Capital Management, LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,079,509 shares of VYGR stock, worth $6.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,079,509
Previous 1,072,769 0.63%
Holding current value
$6.24 Million
Previous $8.49 Million 25.57%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.77 - $9.27 $38,889 - $62,479
6,740 Added 0.63%
1,079,509 $6.32 Million
Q2 2024

Aug 09, 2024

BUY
$7.42 - $10.54 $745,005 - $1.06 Million
100,405 Added 10.33%
1,072,769 $8.49 Million
Q1 2024

May 13, 2024

BUY
$7.15 - $10.84 $2.1 Million - $3.18 Million
293,486 Added 43.23%
972,364 $9.05 Million
Q4 2023

Feb 13, 2024

BUY
$6.28 - $8.81 $200,539 - $281,329
31,933 Added 4.94%
678,878 $5.73 Million
Q3 2023

Nov 13, 2023

BUY
$7.55 - $11.25 $428,009 - $637,762
56,690 Added 9.6%
646,945 $5.01 Million
Q2 2023

Aug 11, 2023

BUY
$6.94 - $13.99 $2.2 Million - $4.43 Million
317,000 Added 116.01%
590,255 $6.76 Million
Q1 2023

May 15, 2023

BUY
$6.0 - $10.78 $3,102 - $5,573
517 Added 0.19%
273,255 $2.11 Million
Q4 2022

Feb 13, 2023

BUY
$4.94 - $6.61 $8,477 - $11,342
1,716 Added 0.63%
272,738 $1.66 Million
Q3 2022

Nov 14, 2022

BUY
$5.57 - $7.47 $1,671 - $2,241
300 Added 0.11%
271,022 $1.6 Million
Q2 2022

Aug 12, 2022

BUY
$4.82 - $10.09 $33,860 - $70,882
7,025 Added 2.66%
270,722 $1.6 Million
Q1 2022

May 13, 2022

SELL
$2.75 - $9.44 $242,734 - $833,240
-88,267 Reduced 25.08%
263,697 $2.01 Million
Q4 2021

Feb 11, 2022

BUY
$2.47 - $5.55 $181,095 - $406,914
73,318 Added 26.31%
351,964 $953,000
Q3 2021

Nov 12, 2021

BUY
$2.63 - $4.12 $1,367 - $2,142
520 Added 0.19%
278,646 $732,000
Q2 2021

Aug 13, 2021

SELL
$3.94 - $5.44 $735,566 - $1.02 Million
-186,692 Reduced 40.16%
278,126 $1.15 Million
Q1 2021

May 12, 2021

BUY
$4.61 - $9.04 $337,276 - $661,384
73,162 Added 18.68%
464,818 $2.19 Million
Q4 2020

Feb 12, 2021

SELL
$7.15 - $12.28 $35,657 - $61,240
-4,987 Reduced 1.26%
391,656 $2.8 Million
Q3 2020

Nov 13, 2020

SELL
$10.01 - $13.75 $83,693 - $114,963
-8,361 Reduced 2.06%
396,643 $4.23 Million
Q2 2020

Aug 13, 2020

BUY
$8.05 - $14.21 $69,938 - $123,456
8,688 Added 2.19%
405,004 $5.11 Million
Q1 2020

May 14, 2020

BUY
$6.8 - $14.66 $85,958 - $185,317
12,641 Added 3.29%
396,316 $3.63 Million
Q4 2019

Feb 13, 2020

BUY
$12.82 - $16.85 $41,370 - $54,374
3,227 Added 0.85%
383,675 $5.35 Million
Q3 2019

Nov 12, 2019

BUY
$16.31 - $28.29 $182,981 - $317,385
11,219 Added 3.04%
380,448 $6.55 Million
Q2 2019

Aug 14, 2019

BUY
$19.18 - $27.88 $1.01 Million - $1.46 Million
52,426 Added 16.55%
369,229 $10.1 Million
Q1 2019

May 14, 2019

BUY
$8.0 - $19.66 $236,312 - $580,736
29,539 Added 10.28%
316,803 $6.06 Million
Q4 2018

Feb 13, 2019

BUY
$8.59 - $18.05 $462,897 - $972,678
53,888 Added 23.09%
287,264 $2.7 Million
Q3 2018

Nov 13, 2018

BUY
$17.11 - $21.74 $2,600 - $3,304
152 Added 0.07%
233,376 $4.42 Million
Q2 2018

Aug 14, 2018

BUY
$16.76 - $23.92 $764,959 - $1.09 Million
45,642 Added 24.33%
233,224 $4.56 Million
Q1 2018

May 15, 2018

BUY
$16.16 - $31.31 $240,929 - $466,800
14,909 Added 8.63%
187,582 $3.52 Million
Q4 2017

Feb 13, 2018

BUY
$12.26 - $25.88 $383,100 - $808,698
31,248 Added 22.1%
172,673 $2.87 Million
Q3 2017

Nov 14, 2017

BUY
$8.37 - $20.59 $613,228 - $1.51 Million
73,265 Added 107.49%
141,425 $2.91 Million
Q2 2017

Aug 14, 2017

BUY
N/A
68,160
68,160 $610,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.